证券代码：002219 证券简称：恒康医疗 编号： | --- | --- | --- | |----------------------|------------------------------|--------------------------------------------------------------| | | | | | 投资者关系活动类 | □ | 特定对象调研 □分析师会议 | | 别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | √ 现场参观 | | | | □其他 | | | 参与单位名称及人 | 信达澳银基金 张培培 杜蜀鹏 | | | 员姓名 | 方正证券 刘亚明 兰兰 | | | 时间 | 2015 年 3 月 11 | 日 15:00—16 ： 00 | | 地点 | 四川成都锦江工业开发区金石路 | 456 号公司会议室 | | 上市公司接待人员 | 董事会秘书 薛迪桦 | | | 姓名 | | | | 投 资 者 关 系 活 动 | | 问：公司的发展战略是否以医疗服务为主？ | | （电话会议）主要 | | 答：公司 ...

证券代码：002219 证券简称：恒康医疗 恒康医疗集团股份有限公司 投资者关系活动记录表 编号：2015-03 | --- | --- | --- | |----------------------|---------------------------|--------------------------------------------------------------| | | | | | 投资者关系活动类 | □ | 特定对象调研 □分析师会议 | | 别 | √媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 | | | 参与单位名称及人 | | 经济观察报 温淑萍，第一财经 黄思瑜，国际金融报 宋璇，中国经 | | 员姓名 | 营报 张荣旺、张亮， | 21 世纪经济报道 饶守春，经济参考报 吴颖君 | | 时间 | 2015 年 9 月 13 | 日、 14 日 | | 地点 | 大连瓦房店第三医院 | | | 上市公司接待人员 | 董事会秘书 金振声 | | | 姓名 | 瓦房店第三医院院长 宋丽华 | | | 投 ...

Group 1: Hospital Operations and Management - The hospital currently serves approximately 1.2 million people across Wafangdian and surrounding townships, with a strong medical workforce supported by annual recruitment from major universities [2] - Wafangdian Third Hospital has 44 original shareholders, with the company acquiring 70% of its shares, establishing a board to guide development while allowing the hospital to manage its operations independently [3] - The two new hospitals in Dalian have approximately 490 and 450 beds, respectively, with potential for expansion based on business growth [3] Group 2: Performance and Market Strategy - Wafangdian Third Hospital has a performance commitment of 91.3 million, utilizing community outreach and free health check-ups to strengthen patient relationships and market coverage [3] - If the performance commitment is not met, the remaining amount will be compensated by the transferor, ensuring the interests of the listed company are protected [3] Group 3: Talent Development and Management - The hospital's core personnel have opportunities for advancement, potentially becoming hospital directors or moving up within the organization, reflecting the company's strong demand for talent during its rapid growth phase [3]

证券代码：002219 证券简称：恒康医疗 编号：2016-03 恒康医疗集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------------|------------------------------------------------------------| | | | | | 投资者关系活动类 | √ 特定对象调研 □分析师会议 | | | 别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 | | | 参与单位名称及人 | 上海洪鑫源实业有限公司 朱建军 | | | 员姓名 | 北京博钰城投资有限公司 章东义 | | | | 沣京资本管理（北京）有限公司 高波 | | | 时间 | 2016 年 7 月 25 | | | 地点 | 公司会议室 | | | 上市公司接待人员 姓名 | 副总经理、董事会秘书：金振声 | | | 投资者关系活动 | 1、医疗行业及公司发展战略 | | | 主要内 ...

证券代码：002219 证券简称：恒康医疗 恒康医疗集团股份有限公司 投资者关系活动记录表 编号：2016-01 | --- | --- | --- | |-----------------------|-------------------------|--------------------------------------------------------------| | | | | | 投资者关系活动类 | √ | 特定对象调研 □分析师会议 | | 别 | | □媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □现场参观 | | | | □ 其他 | | | 参与单位名称及人 | | 智银投资 赵婷，东吴证券 洪阳 | | 员姓名 | | | | 时间 | 2016 年 7 月 12 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人员 姓名 | | 董事会秘书 金振声，证券事务代表 曹维 | | 投 资 者 关 系 活 动 | 1 | 、对公司重点医院及规模介绍 | | （电话会议）主要 | | 公司下属医院包括瓦三、辽渔、盱眙等八家二级医院，新 ...

Group 1: Industry Trends - The aging population and the rise of chronic diseases in China, along with comprehensive health insurance coverage, will continue to create challenges in accessing affordable healthcare services [2] - The private healthcare sector has significant growth potential due to these trends, prompting the company to increase investments and acquisitions in the medical service field [3] Group 2: Company Hospital Overview - Key hospitals under the company include Dalian Wasan Hospital, Xuyi Hospital, Liaoyu Hospital, Ganxi Hospital, and Guang'an Fuyuan Hospital, all of which focus on patient-centered and responsible service [3] - Some hospitals have established a strong local reputation, particularly Wasa Hospital in neurology and neurosurgery, and Liaoyu Hospital in obstetrics and gynecology [3] Group 3: Future Development in Medical Services - The company adheres to a "specialized and comprehensive" approach, expanding medical service scale through both external acquisitions and internal development [3] - Future acquisitions will target profitable medical service entities, while internal efforts will enhance existing departments, particularly in oncology and high-end obstetrics [3] Group 4: Precision Medicine and Pharmaceutical Strategy - The company has acquired Shanghai Jieao Paisi to leverage its advantages in genetic testing, enhancing service offerings across its hospitals [4] - The pharmaceutical segment focuses on the "Duyiwei" series of traditional Chinese medicine and chemical drugs, with plans to adjust sales strategies based on local market conditions to maintain steady growth [4] - The health product market, primarily targeting the mid-to-high-end segment, presents significant future growth opportunities [4]

Group 1: Regulatory Issues - The company received a "Notice of Investigation" from the China Securities Regulatory Commission (CSRC) due to suspected violations of securities laws, leading to a formal investigation [2] - The company has fulfilled its disclosure obligations and has not yet received conclusive opinions from relevant authorities [2] Group 2: Management Changes - Several executives, including former Chairman Que Wenbin, have left the company, which some speculate is related to the strategic shift from pharmaceuticals to healthcare services [2] - The departure of these executives represents a small percentage of the overall management team, and the company believes it will not adversely affect daily operations [2] Group 3: Financial Performance - In the first half of the year, sales expenses increased by 334.40%, primarily due to increased costs associated with drug and toothpaste sales [3] - The increase in sales expenses is attributed to a low base from the previous year and adjustments in sales policies due to new pharmaceutical regulations [3] Group 4: Hospital Performance - The company has experienced rapid growth in its medical services sector, but some previously acquired hospitals are facing stagnation in organic growth [2] - To address this, the company plans to enhance hospital services through hardware upgrades and software improvements, including the introduction of advanced medical technologies and the establishment of a shared platform for its hospitals [2]

Group 1: Financial Performance - The company reported significant growth in both revenue and net profit for the first half of 2016, attributed to an expanded consolidation scope including hospitals like Wasan, Xuyi, and Fuyuan [2] - The gross profit margin in key regions (Northeast, East China, and Southwest) showed a decline, primarily due to increased investments in talent and discipline construction [2] Group 2: Strategic Planning - The company’s strategy focuses on a "big specialty, strong comprehensive" approach, emphasizing cancer treatment and high-end obstetrics and gynecology [2] - The acquisition of Chongzhou Second Hospital was completed in early September 2016, with intentions to expand further into regions like Lankao and Siyang [2] Group 3: Hospital Management and Expansion - The company currently controls 10 hospitals and has 4 under construction, with a focus on hospitals with significant specialty advantages and a population of over 600,000 in the region [2] - The company aims to leverage synergies among its hospitals through advanced management platforms and data integration [3] Group 4: Market Position and Future Outlook - The private healthcare market in China is on the rise, with significant potential for differentiation from public hospitals through flexibility in operations and service quality [4] - The company believes that the "drug-based medical funding" model will evolve, leading to a healthier and more dynamic healthcare environment [4]

Group 1: Financial Performance - The company experienced significant growth in both revenue and net profit in the first half of 2016, attributed to the expansion of the consolidated financial statement scope and improved internal management practices [2]. - The company invested CNY 177 million in Chongzhou Second Hospital to enhance its construction, leveraging its strong local brand and reputation [2]. Group 2: Hospital Operations - Ganxi Tumor Hospital has officially commenced operations and is building a solid foundation in brand, business development, and talent, while collaborating with Jiangxi Provincial Tumor Hospital to enhance its local influence [2]. - The company focuses on selecting hospitals that are either restructured or can be restructured, prioritizing those with a minimum of secondary class and clear specialty advantages, as well as a concentrated regional population [2]. Group 3: Future Developments - The company is planning to construct hospitals primarily focused on oncology and high-end obstetrics, including Dalian International Tumor Hospital and Mianyang Aibeier Obstetrics Hospital, while integrating existing hospital teams and attracting external talent [2]. - The company has established a centralized procurement center to enhance its bargaining power and achieve cost reduction and efficiency improvements [3].